1. The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours
- Author
-
Svenja Hering, Alexander Nieto, Sebastian Marschner, Jan Hofmaier, Nina-Sophie Schmidt-Hegemann, Vanessa da Silva Mendes, Guillaume Landry, Maximilian Niyazi, Farkhad Manapov, Claus Belka, Stefanie Corradini, and Chukwuka Eze
- Subjects
MR-guided radiotherapy ,Lung cancer ,Radiation oncology ,MR-guided SBRT ,MR-guided SABR ,MR-Linac, SBRT, SABR, lung metastases ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: The aim of this prospective observational study was to evaluate the dosimetry benefits, changes in pulmonary function, and clinical outcome of online adaptive MR-guided SBRT. Methods: From 11/2020–07/2022, 45 consecutive patients with 59 lesions underwent multi-fraction SBRT (3–8 fractions) at our institution. Patients were eligible if they had biopsy-proven NSCLC or lung cancer/metastases diagnosed via clinical imaging. Endpoints were local control (LC) and overall survival (OS). We evaluated PTV/GTV dose coverage, organs at risk exposure, and changes in pulmonary function (PF). Acute toxicity was classified per the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Results: The median PTV was 14.4 cm3 (range: 3.4 – 96.5 cm3). In total 195/215 (91%) plans were reoptimised. In the reoptimised vs. predicted plans, PTV coverage by the prescribed dose increased in 94.6% of all fractions with a median increase in PTV VPD of 5.6% (range: −1.8 – 44.6%, p
- Published
- 2024
- Full Text
- View/download PDF